Company Description
Oaktree Specialty Lending Corporation is a business development company.
The fund specializing in investments in middle market, bridge financing, first and second lien debt financing, unsecured and mezzanine loan, mezzanine debt, senior and junior secured debt, expansions, sponsor-led acquisitions, preferred equity, and management buyouts in small and mid-sized companies.
It seeks to invest in education services, business services, retail and consumer, healthcare, manufacturing, food and restaurants, construction and engineering.
The firm also seeks investment in media, advertising sectors, software, IT services, pharmaceuticals, biotechnology, real estate management and development, chemicals, machinery, and internet and direct marketing retail sectors.
It invests between $5 million to $75 million principally in the form of one-stop, first lien, and second lien debt investments, which may include an equity co-investment component in companies.
The firm invest in companies having enterprise value between $20 million and $150 million and EBITDA between $3 million and $50 million.
The fund has a hold size of up to $75 million and may underwrite transactions up to $100 million. It primarily invests in North America.
The fund seeks to be a lead investor in its portfolio companies.
| Country | United States |
| Founded | 2007 |
| IPO Date | Jun 12, 2008 |
| Industry | Asset Management |
| Sector | Financials |
| CEO | Armen Panossian |
Contact Details
Address: 333 South Grand Avenue, 28th Floor Los Angeles, California 90071 United States | |
| Phone | 213 830 6300 |
| Website | oaktreespecialtylending.com |
Stock Details
| Ticker Symbol | OCSL |
| Exchange | NASDAQ |
| Stock Type | Common Stock |
| Fiscal Year | October - September |
| Reporting Currency | USD |
| CIK Code | 0001414932 |
| CUSIP Number | 67401P108 |
| ISIN Number | US67401P4054 |
| Employer ID | 26-1219283 |
Key Executives
| Name | Position |
|---|---|
| Armen Panossian J.D. | Chief Executive Officer and Chief Investment Officer |
| Mathew M. Pendo | President |
| Dr. Aman Kumar M.D. | Managing Director and Co-Portfolio Manager of Life Sciences Direct Lending |
| Raghav Khanna | Managing Director and Co-Portfolio Manager |
| Christopher McKown | MD,Chief Financial Officer and Treasurer |
| Michael Mosticchio | Investor Relations |
| Mary Gallegly J.D. | MD,General Counsel and Secretary |
| Ashley Pak | Chief Compliance Officer |
| Sandeep Kumar Khorana | Managing Director of Origination |
| Lucia S. Kim | Senior Vice President |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Feb 21, 2025 | 8-K | Current Report |
| Feb 20, 2025 | 497AD | Filing by certain investment companies of Rule 482 advertising |
| Feb 20, 2025 | FWP | Free Writing Prospectus |
| Feb 20, 2025 | 424B2 | Prospectus |
| Feb 10, 2025 | SCHEDULE 13D | Filing |
| Feb 4, 2025 | 8-K | Current Report |
| Feb 4, 2025 | 10-Q | Quarterly Report |
| Jan 17, 2025 | DEF 14A | Other definitive proxy statements |
| Jan 17, 2025 | DEFA14A | Additional definitive proxy soliciting materials and Rule 14(a)(12) material |
| Jan 10, 2025 | DEFA14A | Additional definitive proxy soliciting materials and Rule 14(a)(12) material |